Compare Gilead Sciences, Inc. (GILD) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs ING Groep NV — how do they compare? Gilead Sciences, Inc. trades at $148.65 (market cap $182.40B), while ING Groep NV trades at $33.33 (market cap $93.76B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and ING Groep NV pays the higher dividend (3.95%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and ING Groep NV for 93 Days on average.
| GILD | ING | |
|---|---|---|
Market Cap | $182.40B | $93.76B |
Volume | 4,469,821 | 4,620,220 |
Sector | Health | Financials |
52-Week High | $155.80 | $37.27 |
52-Week Low | $116.74 | $23.66 |
Typical Hold Time | 111 Days | 93 Days |
Enterprise Value | $205.46B | $236.48B |
Dividend Yield | 2.23% | 3.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
ING stock trades at $33.92, down 2.81% today, with a bearish technical outlook despite recent earnings beats. The company shows strong profitability with 28.34% net income margin and 13.49% ROE, supported by management's raised ROE target above 16% for 2027. Recent news highlights strategic focus on organic growth and bolt-on acquisitions while maintaining capital discipline.
While analyst consensus remains strongly bullish with 65% buy ratings, negative cash flow trends and regulatory scrutiny in Australia present near-term risks. The stock's attractive valuation at 12.86 P/E offers potential upside if the company can execute on its growth strategy and improve cash generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
